口服Muvalaplin降低脂蛋白(a):一项随机临床试验
这项2期随机双盲安慰剂对照试验纳入233例脂蛋白(a)≥175 nmol/L且伴动脉粥样硬化性心血管病、糖尿病或家族性高胆固醇血症者,口服Muvalaplin 10、60、240 mg/d或安慰剂12周。Muvalaplin使脂蛋白(a)较安慰剂显著降低,各剂量耐受良好,但对心血管事件的影响需进一步研究。
要点
- Muvalaplin 10、60、240 mg/d较安慰剂使完整脂蛋白(a)降低47.6%、81.7%、85.8%。
- 载脂蛋白(a)法测得降幅分别为40.4%、70.0%、68.9%,呈剂量依赖性。
- 各剂量未观察到安全性或耐受性担忧,高敏C反应蛋白无变化。
核心结论
- Muvalaplin降低完整脂蛋白(a)法和载脂蛋白(a)法测得的脂蛋白(a),且耐受良好。
- Muvalaplin对心血管事件的影响需进一步研究。
研究设计与样本
- 2期、安慰剂对照、随机、双盲试验,在亚洲、欧洲、澳大利亚、巴西和美国的43个中心进行。
- 2022年12月10日至2023年11月22日纳入233例脂蛋白(a)浓度≥175 nmol/L且伴动脉粥样硬化性心血管病、糖尿病或家族性高胆固醇血症的参与者。
- 参与者随机接受口服Muvalaplin 10 mg/d(n=34)、60 mg/d(n=64)、240 mg/d(n=68)或安慰剂(n=67),为期12周。
主要发现
- 完整脂蛋白(a)法:Muvalaplin 10、60、240 mg/d较安慰剂分别降低47.6%(95%CI 35.1%-57.7%)、81.7%(95%CI 78.1%-84.6%)、85.8%(95%CI 83.1%-88.0%)。
- 载脂蛋白(a)法:Muvalaplin 10、60、240 mg/d较安慰剂分别降低40.4%(95%CI 28.3%-50.5%)、70.0%(95%CI 65.0%-74.2%)、68.9%(95%CI 63.8%-73.3%)。
- 载脂蛋白B呈剂量依赖性降低:10 mg/d为8.9%(95%CI -2.2%至18.8%),60 mg/d为13.1%(95%CI 4.4%-20.9%),240 mg/d为16.1%(95%CI 7.8%-23.7%)。
- 高敏C反应蛋白未见变化。
- 任何剂量均未观察到安全性或耐受性担忧。
临床怎么用
- 原文未据此给出推荐。
局限性
- Muvalaplin对心血管事件的影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Muvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain. OBJECTIVES: To determine the effect of muvalaplin on lipoprotein(a) levels and to assess safety and tolerability. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, placebo-controlled, randomized, double-blind trial enrolling 233 participants with lipoprotein(a) concentrations of 175 nmol/L or greater with atherosclerotic cardiovascular disease, diabetes, or familial hypercholesterolemia at 43 sites in Asia, Europe, Australia, Brazil, and the United States between December 10, 2022, and November 22, 2023. INTERVENTIONS: Participants were randomized to receive orally administered muvalaplin at dosages of 10 mg/d (n = 34), 60 mg/d (n = 64), or 240 mg/d (n = 68) or placebo (n = 67) for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the placebo-adjusted percentage change from baseline in lipoprotein(a) molar concentration at week 12, using an assay to measure intact lipoprotein(a) and a traditional apolipoprotein(a)-based assay. Secondary end points included the percentage change in apolipoprotein B and high-sensitivity C-reactive protein. RESULTS: The median age of study participants was 66 years; 33% were female; and 27% identified as Asian, 4% as Black, and 66% as White. Muvalaplin resulted in placebo-adjusted reductions in lipoprotein(a) of 47.6% (95% CI, 35.1%-57.7%), 81.7% (95% CI, 78.1%-84.6%), and 85.8% (95% CI, 83.1%-88.0%) for the 10-mg/d, 60-mg/d, and 240-mg/d dosages, respectively, using an intact lipoprotein(a) assay and 40.4% (95% CI, 28.3%-50.5%), 70.0% (95% CI, 65.0%-74.2%), and 68.9% (95% CI, 63.8%-73.3%) using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were observed at 8.9% (95% CI, -2.2% to 18.8%), 13.1% (95% CI, 4.4%-20.9%), and 16.1% (95% CI, 7.8%-23.7%) at 10 mg/d, 60 mg/d, and 240 mg/d, respectively. No change in high-sensitivity C-reactive protein was observed. No safety or tolerability concerns were observed at any dosage. CONCLUSIONS AND RELEVANCE: Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated. The effect of muvalaplin on cardiovascular events requires further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05563246.
引用
- Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025. PMID: 39556768. doi:10.1001/jama.2024.24017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。